Sugi Predict

Sugi Predict / Compounds / SCHEMBL7926055

SCHEMBL7926055

SCHEMBL7926055

Cc1cc2c(ccn2C)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CB P42338 1/20 0.50
▸ CYP2A6 P11509 3/20 0.45
▸ CYP1A2 P05177 2/20 0.45
▸ PRKCI P41743 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ HSD11B1 P28845 1/20 0.38
▸ POLQ O75417 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ HTR2C P28335 2/20 0.34
▸ LRRK2 Q5S007 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7914260 0.84 PIK3CB (0.65) PIK3CBCYP2A6CYP1A2PRKCIMAPT
SCHEMBL31435644 0.78 CDC7 (0.49) PIK3CBCYP2A6PRKCIMAPTHSD11B1
SCHEMBL21281591 0.78 PIK3CB (0.49) PIK3CBCYP2A6CYP1A2PRKCIMAPT
SCHEMBL20476705 0.78 PIK3CB (0.49) PIK3CBCYP2A6CYP1A2PRKCIMAPT
SCHEMBL18230343 0.78 CDC7 (0.49) PIK3CBCYP2A6PRKCIMAPTHSD11B1
SCHEMBL23346741 0.78 PIK3CB (0.73) PIK3CBCYP2A6PRKCIMAPTHSD11B1
SCHEMBL3792750 0.78 CYP1A2 (0.44) PIK3CBCYP2A6CYP1A2MAPTUHRF1
SCHEMBL19267571 0.78 CYP1A2 (0.44) PIK3CBCYP2A6CYP1A2MAPTUHRF1
SCHEMBL21281472 0.76 PIK3CB (0.46) PIK3CBCYP2A6CYP1A2PRKCIMAPT
SCHEMBL20276284 0.76 PIK3CB (0.46) PIK3CBCYP2A6PRKCIMAPTHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024006403-A2 SELECTIVE HISTONE DEACETYLASE 8 (HDAC8) DEGRADERS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-01-04 — — WO disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 — — US disclosed
US-11034668-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2021-06-15 — — US disclosed
WO-2020146858-A1 HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME ACCRO BIOSCIENCE INC. (KY) 2020-07-16 — — WO disclosed
US-10370358-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2019-08-06 — — US disclosed
US-20180212158-A1 ORGANIC LIGHT-EMITTING DIODE MATERIALS PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2018-07-26 — — US disclosed
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 — — US disclosed
US-20180194746-A1 Compounds For the Treatment of HIV GILEAD SCIENCES, INC. 2018-07-12 — — US disclosed
US-9944619-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2018-04-17 — — US disclosed
US-9944619-B2 Compounds for the treatment of HIV GILEAD SCIENCES, INC. (US) 2018-04-17 — — US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 — — US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 — — US disclosed
WO-2013006738-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2013-01-10 — — WO disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 — — US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 — — US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 — — EP disclosed
US-20110130384-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-02 — — US disclosed
US-20110130384-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-02 — — US disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 — — WO disclosed
WO-2009157196-A1 AMIDE COMPOUND 武田薬品工業株式会社 (JP) 2009-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370358-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN PIK3CB 1256/4885CYP2A6 1207/4885CYP1A2 489/4885
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB PIK3CB 1572/4885CYP2A6 3139/4885CYP1A2 2432/4885
US-20110130384-A1 AMIDE COMPOUND GPR52, CNR2, ARRB1 PIK3CB 4328/4885CYP2A6 1297/4885CYP1A2 631/4885
US-20180194746-A1 Compounds For the Treatment of HIV CCR5, NPC1, FURIN PIK3CB 1256/4885CYP2A6 1207/4885CYP1A2 489/4885
US-20180212158-A1 ORGANIC LIGHT-EMITTING DIODE MATERIALS MSN, DDT, NECTIN4 PIK3CB 3696/4885CYP2A6 2024/4885CYP1A2 1970/4885
US-11034668-B2 Compounds for the treatment of HIV CCR5, NPC1, FURIN PIK3CB 1256/4885CYP2A6 1207/4885CYP1A2 489/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN PIK3CB 1256/4885CYP2A6 1207/4885CYP1A2 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.